Aims: Podoplanin expression in cancer-associated fibroblasts (CAFs) has been proposed as an unfavourable indicator in squamous cell carcinoma of the lung, but little is known about its clinical significance in early-stage lung adenocarcinoma. We evaluated the prognostic impact of podoplanin expression in patients with pathological stage (p-stage) IA lung adenocarcinoma as categorised by the 8th edition of the tumour-node-metastasis classification for lung cancer. Methods and results: Immunohistochemical analyses using anti-podoplanin antibody were performed on resected specimens from 158 patients with p-stage IA lung adenocarcinoma. When more than 10% of cancer cells or CAFs showed immunoreactivity with podoplanin, the specimens were classified as podoplanin-positive. Podoplanin-positive status in cancer cells (n = 8) was not correlated with clinicopathological factors or with patient prognosis. Podoplanin-positive status in CAFs (n = 41) was correlated significantly with poorer tumour differentiation (P < 0.001), the presence of lymphatic invasion (P < 0.001) and highgrade (solid and/or micropapillary) components constituting ≥1% of the entire tumour (P < 0.001). The log-rank test showed that podoplanin-positive status in CAFs was associated significantly with shorter disease-free survival (DFS) (P < 0.001) and disease-specific survival (P = 0.015). In Cox's multivariate analysis, podoplanin-positive status in CAFs had the most significant effect on shorter DFS [hazard ratio (HR) = 4.411, P = 0.004], followed by the presence of high-grade components (HR = 3.581, P = 0.013). Conclusions: Podoplanin expression in CAFs could be an independent predictor of increased risk of recurrence in patients with p-stage IA lung adenocarcinoma.
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Introduction
Adenocarcinoma is the most common histological subtype of lung cancer in most countries, accounting for almost half of all lung cancers. 1 Surgical resection offers a significant chance of cure for patients with early-stage lung adenocarcinoma; however; the 5-year recurrence rate was reported to range from 20 to 39% in patients with pathological stage (p-stage) I disease. 2 Recently, the 8th edition of the tumournode-metastasis (TNM) classification for lung cancer was published. 3 In the new classification, stage IA was divided into stages IA1, IA2 and IA3 according to the greatest dimension of invasive component. The 5-year survival rates of stages IA1, IA2 and IA3 were reported to be 92, 83 and 77%, respectively. 4 In turn, it has been reported that the predominant subtype defined by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society (IASLC/ ATS/ERS) classification system had prognostic value in patients with stage I lung adenocarcinoma. [5] [6] [7] [8] However, few studies have evaluated the clinical impact of the solid and/or micropapillary component (high-grade components). [9] [10] [11] As far as we know, there has been no study validating the clinical value of high-grade components in patients with new TNM p-stage IA lung adenocarcinoma.
Podoplanin, a 38-kDa type I transmembrane glycoprotein consisting of 162 amino acids, was identified as a platelet-aggregation-inducing factor in cancer cells. 12 Podoplanin is also expressed in both cancer cells and stromal fibroblasts, or so-called cancer-associated fibroblasts (CAFs), in lung cancer, [13] [14] [15] [16] [17] [18] and it is considered to regulate tumour progression and metastasis through various mechanisms such as epithelial-mesenchymal transition and platelet aggregation. 19, 20 To our knowledge, there are only two reports that have explored the clinical significance of podoplanin expression in CAFs in patients with lung adenocarcinoma. 13, 18 Moreover, there is no report validating the clinical impact of podoplanin expression in CAFs in patients with p-stage IA lung adenocarcinoma categorised by the new TNM classification. Taken together, the aim of our study was to evaluate the prognostic significance of podoplanin expression in CAFs as well as that of high-grade components in patients with new TNM p-stage IA lung adenocarcinoma.
Patients and methods

P A T I E N T S A N D T U M O U R S P E C I M E N S
From January 2005 to December 2011 at Tottori University Hospital (Tottori, Japan), 224 consecutive patients diagnosed initially with p-stages IA and IB lung adenocarcinoma according to the 7th edition of the TNM classification underwent curative surgical resection for lung cancer with mediastinal lymph node dissection. None had a history of neoadjuvant chemotherapy or radiation therapy. Six cases were excluded for the following reasons: in two cases, tumour specimens were not available; in three cases, death occurred within 30 days after of the operation (pulmonary embolism, adult respiratory distress syndrome, suicide); and in one case, there was a lack of clinical follow-up. Ten cases of invasive mucinous adenocarcinoma were also excluded. All 137 cases with p-stage IA disease as classified according to the 7th edition of the TNM classification were reclassified to p-stages IA1-3 (IA1 in 37 cases, IA2 in 68 and IA3 in 32). Twenty-one of 71 cases classified as p-stage IB according to the 7th edition of the TNM classification were reclassified into p-stages IA1-3 (IA1 in 14 cases, IA2 in four and IA3 in three). Thus, 158 cases were included in this study. The median follow-up time was 82.5 months (range: 8-151 months). The patients' clinicopathological data were obtained from the hospital medical records.
The pathological diagnosis was performed using haematoxylin and eosin (H&E)-stained sections according to the criteria of the current World Health Organisation classification for lung cancer, 1 and all H&E slides were reviewed by Y.K. and Y.U., who had no knowledge of any of the clinical data. The following histopathological factors were evaluated: tumour differentiation, tumour size, size of the invasive component, lymphatic invasion and pleural invasion. Lymphatic invasion was investigated simultaneously during the evaluation of podoplanin expression in cancer cells and CAFs. The size of the invasive component and pleural invasion were evaluated by elastica van Gieson staining. Tumour stage was determined based on the 8th edition of the TNM classification for lung cancer. 3, 4 All cases were classified into five predominant subtypes (lepidic, acinar, papillary, micropapillary and solid) according to the WHO classification of adenocarcinoma. 1 The presence of high-grade components was defined as having a solid and/or micropapillary component occupying ≥1% of the entire tumour. 10, 11 Written informed consent was obtained, and the present study was approved by the ethics committee of the Faculty of Medicine, Tottori University (approval number: 1704A004; 12 April 2017).
I M M U N O H I S T O C H E M I S T R Y
All resected specimens were fixed in 10% neutrally buffered formalin and embedded in paraffin. After the sections (4-lm thick) were deparaffinised and endogenous peroxidase activity was blocked, they were pretreated in citrate buffer (0.01 M, pH 6.0) at 98°C for 40 min. After cooling to room temperature, non-specific binding was blocked by blocking buffer (BLOCK ACE; Megmilk Snow Brand, Sapporo, Japan). The sections were then incubated at 4°C overnight with an antibody for podoplanin (clone D2-40, diluted 1:100; Dako, Glostrup, Denmark). They were then incubated with the EnVision+ System HRP (Dako). Finally, the slides were incubated with diaminobenzidine (DAB) solution (liquid DAB+ substrate, imidazole-HCI buffer, pH 7.5, containing hydrogen peroxide and an antimicrobial agent; Dako) for 5 min, and counterstained with haematoxylin.
Regarding the definition of immunoreactivity, lymphatic endothelium and type I pneumocytes were used as internal positive controls for podoplanin. When more than 10% of cancer cells or CAFs showed a reaction for podoplanin that was equal to that of the positive control, the cases were judged as podoplanin-positive. 15, 16, 18 CAFs were defined as the spindle-shaped cells present in cancer stroma. All slides were evaluated by Y.K. and Y.U., who were blinded to the patients' clinicopathological data.
S T A T I S T I C A L A N A L Y S I S
All statistical analyses were performed using SPSS version 23 (IBM SPSS Statistics; IBM Corporation, Armonk, NY, USA). The association between podoplanin expression status and clinicopathological factors was evaluated by performing non-parametric tests. The v 2 test was used when there were two categorical variables of interest and the Kruskal-Wallis test was used when there were three or more variables. For the survival analysis, two different endpoints, cancer relapse and cancer-related death, were used to calculate disease-free survival (DFS) and disease-specific survival (DSS), respectively. DFS was defined as the period from the date of initial surgery to the date of clinical or pathological cancer relapse. DSS was defined as the period from the date of initial surgery to the date of cancer-related death. The cases of the patients who were alive were censored at the time of their last follow-up visit. The cases of the patients who died from a cause unrelated to their lung cancer or for whom the cause of death was not entirely clear were censored for the purposes of survival analyses. Survival curves were computed according to the Kaplan-Meier method and differences in the DFS and DSS were analysed using the log-rank test. The Cox regression hazard model was used to evaluate the effect of various factors on DFS and DSS in order to observe the independent prognostic value of podoplanin expression status. All tests were two-sided, and P < 0.05 were considered to be statistically significant in all tests.
Results
I M M U N O H I S T O C H E M I S R T Y
Representative immunohistochemical staining patterns of podoplanin are shown in Figure 1 . Immunoreactivity for cancer cells was observed on the cell membrane ( Figure 1C ). Podoplanin expression in cancer cells and CAFs were observed in 5.0% (eight of 158 cases) and in 25.9% (41 of 158 cases), respectively. Of 41 cases with podoplanin-positive CAFs, 35 cases showed 10-50% positivity whereas six cases showed 50-100% positivity. Although the expression pattern of podoplanin showed heterogeneity, the interobserver variability between two pathologists was low.
C L I N I C O P A T H O L O G I C A L C H A R A C T E R I S T I C S A N D A S S O C I A T I O N W I T H P O D O P L A N I N E X P R E S S I O N S T A T U S
The clinicopathological characteristics of the 158 patients with adenocarcinoma are summarised in Table 1 . A total of 158 cases with invasive adenocarcinomas were classified into six subtypes: 10 (6.3%) were classified as MIA, 29 (18.4%) were classified as lepidic-predominant, 26 (16.5%) as papillary-predominant, 73 (46.2%) as acinar-predominant, 18 (11.4%) as solid-predominant and two (1.3%) as micropapillary-predominant.
The associations between the clinicopathological characteristics and podoplanin expression status in both cancer cells and CAFs are shown in Table 2 . Podoplanin-positive status in cancer cells was not correlated with any clinicopathological factors, whereas podoplanin-positive status in CAFs was correlated significantly with male sex (P < 0.001), ever smoker (P < 0.001), higher pathological T classification (P = 0.001), poorer tumour differentiation (P < 0.001), the presence of high-grade components (P < 0.001) and lymphatic invasion (P < 0.001).
E X P R E S S I O N S T A T U S O F H I G H -G R A D E C O M P O N E N T A N D C O R R E L A T I O N W I T H C L I N I C O P A T H O L O G I C A L C H A R A C T E R I S T I C S
Of 55 cases with high-grade components, 30 had only a solid component (solid-predominant in 16 cases, lepidic-predominant in one case, acinar-predominant in nine cases and papillary-predominant in four cases), 18 only micropapillary component (micropapillary-predominant in one case, acinar-predominant in 10 cases and papillary-predominant in seven cases) and seven both solid and micropapillary components (acinar-predominant in two cases, papillary-predominant in two cases, micropapillary-predominant in one case and solid-predominant in two cases). The high-grade component was observed in 0% (none of 10) of pT1mi, 16.7% (five of 30) of pT1a, 34.7% (25 of 72) of pT1b and 54.3% (25 of 46) of pT1c. There was a statistically significant increase in the number of cases with the high-grade component, as pT progress from pTmi to pT1c (P = 0.001).
S U R V I V A L A N A L Y S I S
Thirteen and 10 patients experienced locoregional recurrence and distant recurrence, respectively. showed that high-grade components-present group had a shorter DFS (P < 0.001) and DSS (P = 0.001). Forty-one and 117 patients were podoplanin-positive and -negative in CAFs, respectively. The 5-year DFS rates of the podoplanin-positive and -negative groups were 68.2% (95% CI: 50.7-80.6) and 94.4% (95% CI: 87.9-97.4), respectively. The 5-year DSS rates of the two groups were 91.8% (95% CI: 76.7-97.3) and 99.1% (95% CI: 93.9-99.9), respectively. The logrank test showed that podoplanin-positive status in CAFs had significantly shorter DFS (P < 0.001) and DSS (P = 0.015) (Figure 3 ). The DFS and DSS according to the podoplanin-positive status in cancer cells were not significant (P = 0.860 and P = 0.437, respectively), according to the log-rank test. Univariate analyses showed a significant correlation between shorter DFS and podoplanin-positive status in CAFs (P < 0.001), higher pathological T classification (P = 0.014), the presence of lymphatic invasion (P = 0.001) and high-grade components (P < 0.001) ( Table 3 ). Lymphatic invasion (P = 0.014), highgrade component (P = 0.007) and podoplanin expression in CAFs (P = 0.025) were also correlated with shorter DSS. According to multivariate analysis using the Cox regression hazard model, podoplanin expression in CAFs had the most significant effect on shorter DFS (P = 0.004), followed by the presence of high-grade components (P = 0.013) ( Table 4) .
Discussion
Several studies have reported that podoplanin expression in cancer cells or CAFs had a prognostic impact in squamous cell carcinoma of the lung, 14-17 but CAFs, Cancer-associated fibroblasts.
there have been only two reports validating the clinical impact of podoplanin expression in CAFs in patients with lung adenocarcinoma. 13, 18 Kawase et al. revealed that podoplanin expression in CAFs was associated significantly with shorter overall survival (OS) in 177 cases of lung adenocarcinoma including p-stages I-IV cases, 13 but they failed to show that it was an independent prognostic factor according to multivariate analysis. Ito et al. reported that podoplanin-positive CAFs were the most powerful independent risk factor for recurrence in 304 patients with stage I lung adenocarcinoma based on the 7th edition of the TNM classification of malignant tumours. 18 Although our results were similar to theirs, our cohort may be stratified more strictly, as the new 8th edition of the TNM classification of malignant tumours was used. The new TNM classification system adopted only the greatest dimension of invasive size as the pathological tumour size (pT), and the pT1 classification was newly divided into pT1a, pT1b and pT1c, as the 5-year survival rates differed among p-stage IA1 (pT1aN0M0), IA2 (pT1bN0M0) and IA3 (pT1cN0M0). 4 Our cohort also showed that patients with p-stage IA3 had a significantly shorter DFS than patients with combined pstages IA1 and IA2. However, we failed to demonstrate that podoplanin expression in CAFs was an independent prognostic factor for DSS according to multivariate analysis. The main reason for our failure is probably our small number of cases and the shorter follow-up period in our study; however; it has been considered that DFS reflects more accurately the biological behaviour of tumours in stage I lung adenocarcinoma, 5 and that post-recurrence survival in resected stage I non-small cell carcinoma was poor. 21 Thus, it remains to be resolved whether podoplanin expression in CAFs could be an independent predictor for shorter DSS in patients with p-stage IA lung adenocarcinoma. Alternatively, we evaluated simultaneously a well-recognised prognostic factor, i.e. the solid and micropapillary patterns, for lung adenocarcinoma. These patterns have been well recognised as markers for aggressive tumour biology characterised by high rates of recurrence and poor survival, even in completely resected early-stage tumours. 5-8 Cha et al. reported that the presence of the micropapillary subtype (≥1% of the entire tumour) was a single prognostic factor for OS in lung adenocarcinoma measuring ≤3 cm. 9 However, it has been reported that a Japanese cohort of 347 patients with stage IA lung adenocarcinoma had a low frequency (1.7%) of the micropapillary-predominant pattern, which was similar to the finding in our cohort (1.4%). 8 Conversely, we have reported previously that the presence of solid and/or micropapillary components (≥ 1% of the entire tumour) predicted a worse prognosis in patients with acinar-and papillarypredominant lung adenocarcinoma measuring ≤3 cm. 11 Therefore, we focused upon the clinical significance of the presence of solid and/or micropapillary components (≥ 1% of the entire tumour) in patients with new TNM p-stage IA lung adenocarcinoma. The inclusion of both the new TNM classification and well-known established prognostic factors in our analysis strengthened the reliability of our results.
In conclusion, we have demonstrated for the first time that podoplanin expression in CAFs was the most powerful independent risk factor for recurrence in patients with new TNM p-stage IA lung adenocarcinoma. Due to the recent improvement in imaging techniques, stage I lung adenocarcinoma is detected more often than in the past; therefore, it is important to identify markers in order to be able to stratify patients with a small but aggressive phenotype, so that appropriate treatment strategies can be selected as early as possible. The limitations of our study were the small number of patients and its retrospective nature; therefore, further studies with larger series of patients and a longer follow-up period are needed. Our study suggested that immunohistochemical analysis using antibodies for podoplanin, which has been performed routinely, could be useful not only for the detection of lymphatic vessel invasion but also for the prediction of an aggressive tumour phenotype in patients with p-stage IA lung adenocarcinoma who are expected to have a favourable prognosis.
